Merck and Glenmark Face Class Action Over Zetia Monopoly Claims

Drug Industry Daily
Merck and Glenmark engaged in anticompetitive behavior by keeping a generic version of Zetia off the market, creating a monopoly and manipulating the drug price, according to a newly filed lawsuit seeking class action status in a Virginia federal court.

To View This Article:


Subscribe To Drug Industry Daily